Source 1primary paper2026MED
Toolkit/multi-antigen CARs
multi-antigen CARs
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Multi-antigen CARs and targeted gene edits (for example, PD-1 disruption) may limit antigen escape.
Usefulness & Problems
Why this is useful
Multi-antigen CARs are presented as a next-generation CAR design strategy. The abstract specifically links them to limiting antigen escape.; reducing antigen escape in prostate cancer CAR-T therapy
Source:
Multi-antigen CARs are presented as a next-generation CAR design strategy. The abstract specifically links them to limiting antigen escape.
Source:
reducing antigen escape in prostate cancer CAR-T therapy
Problem solved
They are intended to address antigen heterogeneity and escape, which are named barriers to CAR-T efficacy in prostate cancer.; addresses antigen heterogeneity and antigen escape
Source:
They are intended to address antigen heterogeneity and escape, which are named barriers to CAR-T efficacy in prostate cancer.
Source:
addresses antigen heterogeneity and antigen escape
Problem links
addresses antigen heterogeneity and antigen escape
LiteratureThey are intended to address antigen heterogeneity and escape, which are named barriers to CAR-T efficacy in prostate cancer.
Source:
They are intended to address antigen heterogeneity and escape, which are named barriers to CAR-T efficacy in prostate cancer.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Mechanisms
multi-antigen targetingTechniques
No technique tags yet.
Target processes
No target processes tagged yet.
Implementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationoperating role: actuator
requires engineering CAR designs that address more than one antigen
The abstract does not state that multi-antigen CARs overcome the suppressive TME, safety issues, or the rarity of durable remissions on their own.; abstract does not report durable remission or definitive clinical efficacy
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
Cytokine-armed armored CAR-T cells may enhance T cell infiltration and persistence despite the suppressive tumor microenvironment in prostate cancer.
Next-generation CAR designs, such as cytokine-armed CAR-T cells, may enhance T cell infiltration and persistence despite the suppressive TME.
Multi-antigen CARs and targeted gene edits such as PD-1 disruption may limit antigen escape in prostate cancer CAR-T therapy.
Multi-antigen CARs and targeted gene edits (for example, PD-1 disruption) may limit antigen escape.
Modulating tumor metabolism and immune checkpoints can reverse T cell exhaustion in the prostate cancer CAR-T context.
Modulating tumor metabolism and immune checkpoints can reverse T cell exhaustion.
Approval Evidence
1 source1 linked approval claimfirst-pass slug multi-antigen-cars
Multi-antigen CARs and targeted gene edits (for example, PD-1 disruption) may limit antigen escape.
Source:
engineering strategysupports
Multi-antigen CARs and targeted gene edits such as PD-1 disruption may limit antigen escape in prostate cancer CAR-T therapy.
Multi-antigen CARs and targeted gene edits (for example, PD-1 disruption) may limit antigen escape.
Source:
Comparisons
Source-stated alternatives
The source contrasts this strategy with targeted gene edits such as PD-1 disruption, cytokine-armed CAR-T cells, metabolic reprogramming, and combination therapies.
Source:
The source contrasts this strategy with targeted gene edits such as PD-1 disruption, cytokine-armed CAR-T cells, metabolic reprogramming, and combination therapies.
Source-backed strengths
may limit antigen escape
Source:
may limit antigen escape
Compared with armored CAR-T cells
The source contrasts this strategy with targeted gene edits such as PD-1 disruption, cytokine-armed CAR-T cells, metabolic reprogramming, and combination therapies.
Shared frame: source-stated alternative in extracted literature
Strengths here: may limit antigen escape.
Relative tradeoffs: abstract does not report durable remission or definitive clinical efficacy.
Source:
The source contrasts this strategy with targeted gene edits such as PD-1 disruption, cytokine-armed CAR-T cells, metabolic reprogramming, and combination therapies.
Compared with CAR-T
The source contrasts this strategy with targeted gene edits such as PD-1 disruption, cytokine-armed CAR-T cells, metabolic reprogramming, and combination therapies.
Shared frame: source-stated alternative in extracted literature
Strengths here: may limit antigen escape.
Relative tradeoffs: abstract does not report durable remission or definitive clinical efficacy.
Source:
The source contrasts this strategy with targeted gene edits such as PD-1 disruption, cytokine-armed CAR-T cells, metabolic reprogramming, and combination therapies.
Compared with CAR-T cells
The source contrasts this strategy with targeted gene edits such as PD-1 disruption, cytokine-armed CAR-T cells, metabolic reprogramming, and combination therapies.
Shared frame: source-stated alternative in extracted literature
Strengths here: may limit antigen escape.
Relative tradeoffs: abstract does not report durable remission or definitive clinical efficacy.
Source:
The source contrasts this strategy with targeted gene edits such as PD-1 disruption, cytokine-armed CAR-T cells, metabolic reprogramming, and combination therapies.
Compared with CAR-T cell therapy
The source contrasts this strategy with targeted gene edits such as PD-1 disruption, cytokine-armed CAR-T cells, metabolic reprogramming, and combination therapies.
Shared frame: source-stated alternative in extracted literature
Strengths here: may limit antigen escape.
Relative tradeoffs: abstract does not report durable remission or definitive clinical efficacy.
Source:
The source contrasts this strategy with targeted gene edits such as PD-1 disruption, cytokine-armed CAR-T cells, metabolic reprogramming, and combination therapies.
Compared with CAR-T therapy
The source contrasts this strategy with targeted gene edits such as PD-1 disruption, cytokine-armed CAR-T cells, metabolic reprogramming, and combination therapies.
Shared frame: source-stated alternative in extracted literature
Strengths here: may limit antigen escape.
Relative tradeoffs: abstract does not report durable remission or definitive clinical efficacy.
Source:
The source contrasts this strategy with targeted gene edits such as PD-1 disruption, cytokine-armed CAR-T cells, metabolic reprogramming, and combination therapies.
Compared with Chimeric Antigen Receptor (CAR) T-cell therapy
The source contrasts this strategy with targeted gene edits such as PD-1 disruption, cytokine-armed CAR-T cells, metabolic reprogramming, and combination therapies.
Shared frame: source-stated alternative in extracted literature
Strengths here: may limit antigen escape.
Relative tradeoffs: abstract does not report durable remission or definitive clinical efficacy.
Source:
The source contrasts this strategy with targeted gene edits such as PD-1 disruption, cytokine-armed CAR-T cells, metabolic reprogramming, and combination therapies.
Compared with chimeric antigen receptor T cells
The source contrasts this strategy with targeted gene edits such as PD-1 disruption, cytokine-armed CAR-T cells, metabolic reprogramming, and combination therapies.
Shared frame: source-stated alternative in extracted literature
Strengths here: may limit antigen escape.
Relative tradeoffs: abstract does not report durable remission or definitive clinical efficacy.
Source:
The source contrasts this strategy with targeted gene edits such as PD-1 disruption, cytokine-armed CAR-T cells, metabolic reprogramming, and combination therapies.
Compared with Chimeric antigen receptor T-cell therapy
The source contrasts this strategy with targeted gene edits such as PD-1 disruption, cytokine-armed CAR-T cells, metabolic reprogramming, and combination therapies.
Shared frame: source-stated alternative in extracted literature
Strengths here: may limit antigen escape.
Relative tradeoffs: abstract does not report durable remission or definitive clinical efficacy.
Source:
The source contrasts this strategy with targeted gene edits such as PD-1 disruption, cytokine-armed CAR-T cells, metabolic reprogramming, and combination therapies.
Ranked Citations
- 1.